Mirapezol (Pramipexole Dihydrochloride)

Pramipexole dihydrochloride, the active ingredient in Mirapezol, is a dopamine agonist presented as an oral formulation for oral use. It is employed in the management of Parkinson's disease and restless legs syndrome in adult patients.

GNH USA supplies Mirapezol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirapezol is a dopamine agonist used in movement‑disorder therapy.

- Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor. - Restless legs syndrome: reduces the urge to move the legs and associated discomfort.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: sensation of light‑headedness, especially on standing. - Somnolence: increased sleepiness during the day. - Headache: transient cranial discomfort.

Serious or Rare Side Effects: - Hallucinations: visual or auditory disturbances requiring medical review. - Impulse control disorders: compulsive gambling, shopping or eating. - Sudden onset of sleep: unexpected sleep episodes, especially when driving. - Severe depression or suicidal thoughts: monitor mood changes closely. - Orthostatic hypotension: marked drop in blood pressure upon standing.

Before initiating therapy, consider the following precautions: - Dose titration: start with a low dose and increase gradually to minimize adverse effects. - Renal impairment: adjust dose based on creatinine clearance. - Cardiovascular disease: monitor blood pressure and heart rate regularly. - Psychiatric history: assess risk of hallucinations, depression or impulse‑control issues. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Pramipexole may interact with several medicines.

Major Interactions (Avoid): - MAO‑B inhibitors: concurrent use can precipitate hypertensive crisis. - Antipsychotics: may antagonize pramipexole’s dopaminergic effect. - Strong CYP2D6 inhibitors: can increase pramipexole plasma concentrations.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive blood‑pressure‑lowering effect, monitor for hypotension. - Alcohol: may enhance somnolence and dizziness. - Other dopamine agonists: risk of additive side‑effects, adjust dosing as needed.